Divalproex Sodium
Product Images NDC 67046-138

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 67046-138). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Contract Pharmacy Services-pa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium (Divalprodrplr Figure 01)

Chemical structure of divalproex sodium showing its molecular arrangement with carbon, hydrogen, oxygen, and sodium ions.*

FDA Label Image

Divalproex Sodium Dr Tablets (Divalprodrplr Figure 02)

A bar chart comparing percentage values for two studies labeled Study 1 (YMRS) and Study 2 (MRS). Each study compares a placebo group (PBO) with a Divalproex Sodium treatment group (DV/DRT), showing higher percentages for the treatment group in both studies.*

FDA Label Image

Divalproex Sodium Dr Tablets (Divalprodrplr Figure 03)

A line graph comparing the percentage reduction in CFR8 ratio in patients treated with Divalproex Sodium delayed-release tablets versus placebo. The x-axis shows the percentage of patients, and the y-axis shows the percentage reduction in CFR8 ratio, indicating improvement or worsening.*

FDA Label Image

Divalproex Sodium Dr Tablets (Divalprodrplr Figure 04)

A cumulative percentage plot showing the reduction in CP8 Auto scores for patients treated with Divalproex Sodium at high dose and low dose. The x-axis represents the percentage of patients from 100% to 0%, and the y-axis indicates the percentage reduction in CP8 Auto scores from -100% to 100%. The chart includes labels for improvement, no change, and worsening.*

FDA Label Image

Divalproex Sodium Dr Tablets (Divalprodrplr Figure 05)

A bar chart comparing numerical values between Placebo and DVDRT across two studies, labeled Study 1 and Study 2. The vertical axis appears to measure a quantity ranging from 0 to 6, showing higher values for Placebo groups in both studies.*

FDA Label Image

Divalproex Sodium Delayed-release Tablets Usp, 250 mg (Divalprodrplr Figure 07)

Label for Divalproex Sodium 250 mg delayed-release tablets, bottle of 30, labeled by Contract Pharmacy Services-PA. The label includes dosage strength, Rx only status, lot number MN6569, pill ID ZA07, and an expiration date of 06/02/15. Storage instructions specify 20-25°C (68-77°F). The label also notes each tablet contains divalproex sodium equivalent to 250 mg valproic acid.*

FDA Label Image

Divalproex Sodium Delayed-release Tablets Usp, 500 mg (Divalprodrplr Figure 08)

Label for Divalproex Sodium 500 mg delayed-release tablets, bottle of 30. The label includes dosage instruction reference, storage condition (20-25°C), and confirms each tablet contains 500 mg equivalent valproic acid. Packaged by Contract Pharmacy Services-PA with NDC 67046-138-30 and additional lot, expiration, and barcode information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.